Corvus Pharmaceuticals (CRVS)

Corvus Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.

Download CSV

18.0M

Short interest

settlement 2026-10-15

14.9

Days to cover

+1.6 days vs prior

65.1%

Short share of volume

2026-11-02

1,640

Fails to deliver

settlement 2026-09-29

Tue 10 Nov

Next earnings

estimated date

Insider flow, 90 days

0 buys, 0 sells

As of 2026-11-02.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 15 October 2026, short interest in CRVS is 17,967,756 shares, up 787,415 shares over the last month. Over the last 48 readings it ranged from 2,925,030 shares (31 October 2024) to 19,127,098 shares (14 August 2026). The latest reading sits at the top of that range. At the reported average volume of 1.2M shares a day that is 14.9 days to cover.

Embed this chart.The embed keeps its attribution line.

<iframe src="https://xoomar.com/embed/stocks/crvs" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

Preview Dark previewAdd ?theme=dark to the src for a dark chart.

Settlement	Shares short	Change	Avg daily volume	Days to cover
2026-10-15	17,967,756	+1.0%	1,203,205	14.93
2026-09-30	17,797,751	+3.6%	1,336,813	13.31
2026-09-15	17,180,341	-9.7%	946,307	18.16
2026-08-31	19,017,840	-0.6%	641,670	29.64
2026-08-14	19,127,098	+4.5%	849,105	22.53
2026-07-31	18,310,256	+1.4%	813,944	22.50
2026-07-15	18,061,919	-4.0%	1,434,623	12.59
2026-06-30	18,819,891	+5.2%	1,520,069	12.38
2026-06-15	17,882,834	+3.2%	1,244,138	14.37
2026-05-29	17,324,311	-8.4%	2,051,054	8.45
2026-05-15	18,910,283	+2.9%	1,579,015	11.98
2026-04-30	18,385,941	+8.6%	1,593,299	11.54
2026-04-15	16,928,111	-0.1%	777,574	21.77
2026-03-31	16,951,894	+5.6%	1,528,575	11.09
2026-03-13	16,054,916	+0.3%	1,091,580	14.71
2026-02-27	16,009,857	+7.6%	1,205,016	13.29
2026-02-13	14,883,150	+1.4%	1,517,092	9.81
2026-01-30	14,678,521	+27.8%	13,502,350	1.09
2026-01-15	11,486,255	-2.8%	1,524,014	7.54
2025-12-31	11,816,663	+25.9%	1,825,586	6.47
2025-12-15	9,383,518	-4.4%	1,397,824	6.71
2025-11-28	9,812,924	-0.9%	756,405	12.97
2025-11-14	9,902,822	+9.7%	1,135,166	8.72
2025-10-31	9,028,415	+2.2%	1,016,507	8.88
2025-10-15	8,833,502	-12.5%	1,124,607	7.85
2025-09-30	10,096,570	+4.4%	798,741	12.64
2025-09-15	9,670,508	+0.8%	628,977	15.37
2025-08-29	9,593,924	+3.2%	545,025	17.60
2025-08-15	9,294,023	+5.7%	494,223	18.81
2025-07-31	8,792,759	-2.1%	444,258	19.79
2025-07-15	8,984,611	+0.9%	566,620	15.86
2025-06-30	8,904,387	+12.2%	1,531,874	5.81
2025-06-13	7,939,714	+12.1%	899,988	8.82
2025-05-30	7,080,956	-2.1%	658,871	10.75
2025-05-15	7,231,927	+25.2%	2,016,541	3.59
2025-04-30	5,774,289	+8.1%	968,288	5.96
2025-04-15	5,340,977	+8.6%	825,776	6.47
2025-03-31	4,916,177	-8.8%	802,393	6.13
2025-03-14	5,391,839	+0.8%	568,293	9.49
2025-02-28	5,348,002	-6.7%	735,089	7.28
2025-02-14	5,732,606	-6.2%	376,784	15.21
2025-01-31	6,108,482	+11.0%	442,699	13.80
2025-01-15	5,501,782	+1.3%	649,002	8.48
2024-12-31	5,429,471	+26.1%	2,441,320	2.22
2024-12-13	4,305,523	+22.5%	796,874	5.40
2024-11-29	3,514,354	+6.5%	640,162	5.49
2024-11-15	3,300,809	+12.8%	1,138,921	2.90
2024-10-31	2,925,030	+19.6%	1,055,217	2.77

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 2 November 2026, the short share of CRVS volume is 65.1%, up 9.0 points over the last five sessions. Over the last 30 readings it ranged from 28.0% (8 October 2026) to 70.4% (23 September 2026). The latest reading is 10.2 points above the 30-session average of 55.0%, on 219K shares reported.

Date	Short volume	Total volume	Short share	Exempt
2026-11-02	143K	219K	65.1%	13
2026-10-30	155K	287K	53.9%	1,443
2026-10-29	160K	269K	59.6%	0
2026-10-28	145K	291K	49.7%	193
2026-10-27	219K	383K	57.2%	4
2026-10-26	178K	317K	56.1%	75
2026-10-23	229K	353K	65.0%	255
2026-10-22	270K	407K	66.3%	0
2026-10-21	187K	306K	61.0%	0
2026-10-20	189K	347K	54.6%	20,723
2026-10-19	183K	309K	59.2%	0
2026-10-16	198K	326K	60.8%	0
2026-10-15	212K	343K	61.8%	0
2026-10-14	224K	388K	57.7%	0
2026-10-13	446K	656K	68.1%	0
2026-10-12	104K	215K	48.6%	0
2026-10-09	177K	399K	44.4%	0
2026-10-08	168K	600K	28.0%	0
2026-10-07	182K	469K	38.7%	0
2026-10-06	214K	541K	39.5%	724
2026-10-05	139K	269K	51.6%	0
2026-10-02	236K	568K	41.5%	0
2026-10-01	216K	515K	42.0%	5,568
2026-09-30	145K	286K	50.8%	1,675
2026-09-29	132K	261K	50.6%	0
2026-09-28	299K	453K	65.9%	7,500
2026-09-25	255K	405K	63.0%	0
2026-09-24	237K	387K	61.3%	0
2026-09-23	250K	355K	70.4%	0
2026-09-22	137K	242K	56.5%	0

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 29 September 2026, the fails-to-deliver balance in CRVS is 1,640 shares, down 4,400 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (8 July 2026) to 42,687 shares (21 September 2026). The latest reading sits at the bottom of that range.

Settlement	Shares failed	Price	Value
2026-09-29	1,640	$11.87	$19K
2026-09-22	6,040	$12.42	$75K
2026-09-21	42,687	$12.56	$536K
2026-09-18	2,705	$12.55	$34K
2026-09-11	3,661	$12.94	$47K
2026-09-04	673	$14.65	$10K
2026-09-03	19,099	$14.20	$271K
2026-09-02	3,049	$14.27	$44K
2026-08-31	3,186	$14.16	$45K
2026-08-27	311	$14.73	$5K
2026-08-25	895	$14.09	$13K
2026-08-19	7,004	$14.83	$104K
2026-08-17	2,280	$14.89	$34K
2026-08-12	5,253	$14.73	$77K
2026-08-05	36	$13.92	$501
2026-07-29	9,962	$13.31	$133K
2026-07-22	3,643	$14.47	$53K
2026-07-21	15,919	$14.10	$224K
2026-07-17	248	$14.27	$4K
2026-07-09	2,564	$16.08	$41K
2026-07-08	1	$15.63	$16
2026-07-01	8,584	$14.94	$128K
2026-06-30	12,844	$14.48	$186K
2026-06-23	2,679	$12.56	$34K
2026-06-16	1,504	$11.90	$18K
2026-06-15	1,000	$11.93	$12K
2026-06-12	2,932	$11.60	$34K
2026-06-03	700	$11.69	$8K
2026-06-02	732	$12.08	$9K
2026-05-19	6,745	$12.21	$82K

Insider trades

SEC Form 4, newest first. JSON

No open-market insider trades were reported for CRVS in the last 90 days. The most recent filings are listed below. Latest filing: Moore David Scott (Director) on 2026-06-11.

Date	Insider	Title	Type	Shares	Price	Value	Owned after
2026-06-11	Moore David Scott	Director	Buy	22K	$11.53	$250K	22K
2026-05-18	MILLER RICHARD A MD	President and CEO	Buy	2K	$12.01	$23K	1.2M
2026-05-18	MILLER RICHARD A MD	President and CEO	Buy	5K	$12.05	$60K	1.2M
2026-01-28	Thompson Peter A.	Director, 10% owner	Exercise or conversion	15K	$2.12	$32K	210K
2026-01-28	Thompson Peter A.	Director, 10% owner	Exercise or conversion	15K	$1.64	$25K	195K
2026-01-28	Thompson Peter A.	Director, 10% owner	Exercise or conversion	15K	$2.49	$37K	180K
2026-01-28	Thompson Peter A.	Director, 10% owner	Exercise or conversion	15K	$0.96	$14K	165K
2026-01-28	Thompson Peter A.	Director, 10% owner	Exercise or conversion	15K	$0.99	$15K	150K
2026-01-28	Thompson Peter A.	Director, 10% owner	Exercise or conversion	15K	$2.60	$39K	135K
2026-01-28	Thompson Peter A.	Director, 10% owner	Exercise or conversion	15K	$2.74	$41K	120K
2026-01-28	Thompson Peter A.	Director, 10% owner	Exercise or conversion	15K	$3.27	$49K	105K
2026-01-28	Thompson Peter A.	Director, 10% owner	Exercise or conversion	15K	$2.00	$30K	90K
2026-01-28	Thompson Peter A.	Director, 10% owner	Exercise or conversion	15K	$3.61	$54K	75K
2026-01-28	Thompson Peter A.	Director, 10% owner	Exercise or conversion	15K	$12.50	$188K	60K
2026-01-28	Thompson Peter A.	Director, 10% owner	Exercise or conversion	15K	$9.70	$146K	45K
2026-01-28	Thompson Peter A.	Director, 10% owner	Exercise or conversion	30K	$15.00	$450K	30K
2025-06-27	ORBIMED ADVISORS LLC	Director, 10% owner	Sell	1.2M	$4.16	$4.9M	7.2M
2025-06-27	ORBIMED ADVISORS LLC	Director, 10% owner	Exercise (in or at the money)	1.4M	$3.50	$4.9M	8.3M
2025-06-27	Thompson Peter A.	Director, 10% owner	Sell	1.2M	$4.16	$4.9M	7.2M
2025-06-27	Thompson Peter A.	Director, 10% owner	Exercise (in or at the money)	1.4M	$3.50	$4.9M	8.3M
2025-06-04	Jones William Benton	See Remarks	Exercise or conversion	19K	$3.50	$68K	173K
2025-05-07	MILLER RICHARD A MD	President and CEO	Exercise or conversion	559K	$3.50	$2.0M	1.1M
2024-05-10	MILLER RICHARD A MD	President and CEO	Gift	302K	$0.00	$0	1.2M
2024-05-06	MILLER RICHARD A MD	President and CEO	Buy	578K	$1.73	$999K	578K
2024-05-06	Jones William Benton	See Remarks	Buy	20K	$1.73	$35K	154K
2023-05-15	Grais Linda	Director	Buy	10K	$2.45	$25K	10K
2022-12-20	Jones William Benton	See Remarks	Buy	20K	$0.79	$16K	134K
2022-12-14	MILLER RICHARD A MD	President and CEO	Buy	10K	$0.78	$8K	1.5M
2022-12-14	LEA LEIV	Chief Financial Officer	Buy	4K	$0.84	$3K	133K
2022-12-13	MILLER RICHARD A MD	President and CEO	Buy	50K	$0.74	$37K	1.5M
2022-12-13	LEA LEIV	Chief Financial Officer	Buy	30K	$0.74	$22K	129K
2022-09-28	MILLER RICHARD A MD	President and CEO	Buy	25K	$0.76	$19K	1.4M
2022-09-20	MILLER RICHARD A MD	President and CEO	Buy	12K	$0.81	$10K	1.4M
2022-09-20	MILLER RICHARD A MD	President and CEO	Buy	5K	$0.82	$4K	1.4M
2022-09-20	MILLER RICHARD A MD	President and CEO	Buy	3K	$0.82	$2K	1.4M
2022-06-27	MILLER RICHARD A MD	President and CEO	Buy	5K	$1.00	$5K	1.3M
2022-06-24	MILLER RICHARD A MD	President and CEO	Buy	5K	$1.03	$5K	1.3M
2022-06-06	MILLER RICHARD A MD	President and CEO	Buy	890	$1.01	$899	1.3M
2022-06-02	MILLER RICHARD A MD	President and CEO	Buy	170	$0.97	$165	1.3M
2022-06-02	MILLER RICHARD A MD	President and CEO	Buy	5K	$0.98	$5K	1.3M
2022-03-31	MILLER RICHARD A MD	President and CEO	Buy	15K	$1.64	$25K	1.3M
2022-03-17	MILLER RICHARD A MD	President and CEO	Buy	5K	$1.59	$8K	1.3M
2022-03-17	LEA LEIV	Chief Financial Officer	Buy	14K	$1.65	$23K	99K
2022-03-16	LEA LEIV	Chief Financial Officer	Buy	35K	$1.54	$54K	85K
2022-03-15	MILLER RICHARD A MD	President and CEO	Buy	25K	$1.47	$37K	1.3M
2021-10-01	EcoR1 Capital, LLC	TenPercentOwner	Sell	2.0M	$4.96	$9.9M	81K
2021-09-30	EcoR1 Capital, LLC	TenPercentOwner	Sell	3.0M	$5.04	$15.1M	2.1M
2021-09-20	Thompson Peter A.	Director,TenPercentOwner	Sell	1.1M	$6.09	$6.8M	6.9M
2021-09-20	OrbiMed Capital GP V LLC	Director,TenPercentOwner	Sell	1.1M	$6.09	$6.8M	6.9M
2021-08-20	MILLER RICHARD A MD	President and CEO	Buy	10K	$1.93	$19K	1.3M
2021-05-04	MILLER RICHARD A MD	President and CEO	Buy	36K	$2.80	$100K	36K
2021-02-17	MILLER RICHARD A MD	President and CEO	Buy	100K	$3.50	$350K	1.3M
2021-02-17	Thompson Peter A.	Director,TenPercentOwner	Buy	1.3M	$3.50	$4.5M	8.1M
2021-02-17	ORBIMED ADVISORS LLC	Director,TenPercentOwner	Buy	1.3M	$3.50	$4.5M	8.1M
2020-07-08	Novo Holdings A/S	TenPercentOwner	Sell	741K	$5.37	$4.0M	1.4M
2020-07-07	Novo Holdings A/S	TenPercentOwner	Sell	797K	$5.25	$4.2M	2.1M

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

7 holders report 5% or more of CRVS in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is ORBIMED ADVISORS LLC at 10.3% of the class (8,609,091 shares), filed 2026-01-27 for an event on 2026-01-23.

Filed	Form	Holder	Shares	Of class	Event
2026-08-07	13G	STATE STREET CORPORATIONparent holding company	4.5M	5.3%	2026-06-30
2026-07-27	13G/Ano. 2	BlackRock, Inc.parent holding company	6.3M	7.5%	2026-06-30
2026-05-15	13G/Ano. 1	Point72 Asset Management, L.P.partnership	0	0.0%	2026-03-31
2026-05-15	13G/Ano. 1	Steven A. Cohenindividual	0	0.0%	2026-03-31
2026-05-15	13G/Ano. 1	Point72 Capital Advisors, Inc.corporation	0	0.0%	2026-03-31
2026-05-15	13G	Sirenia Capital Management LPinvestment adviser, partnership	6.8M	7.5%	2026-03-31
2026-05-15	13G	Alex Silversteinparent holding company, individual	6.8M	7.5%	2026-03-31
2026-03-26	13G/Ano. 1	The Vanguard Groupinvestment adviser	0	0.0%	2026-03-13
2026-02-13	13G/Ano. 10	Richard A. Millerindividual	6.1M	7.8%	2025-12-31
2026-02-13	13G/Ano. 10	Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985other entity	1.2M	1.6%	2025-12-31
2026-02-13	13G/Ano. 10	Sandra J. Horningindividual	1.2M	1.6%	2025-12-31
2026-02-05	13D/Ano. 1	Adams Street Partners, LLCinvestment adviser	3.3M	3.9%	2026-01-23
2026-02-05	13D/Ano. 1	Adams Street 2012 Direct Fund LPpartnership	715K	0.9%	2026-01-23
2026-02-05	13D/Ano. 1	Adams Street 2014 Direct Fund LPpartnership	736K	0.9%	2026-01-23
2026-02-05	13D/Ano. 1	Adams Street 2011 Direct Fund LPpartnership	695K	0.8%	2026-01-23
2026-02-05	13D/Ano. 1	Adams Street 2013 Direct Fund LPpartnership	541K	0.6%	2026-01-23
2026-02-05	13D/Ano. 1	Adams Street Venture/Growth Fund VI LPpartnership	236K	0.3%	2026-01-23
2026-02-05	13D/Ano. 1	Adams Street 2018 Direct Venture/Growth Fund LPpartnership	127K	0.2%	2026-01-23
2026-02-05	13D/Ano. 1	Adams Street 2016 Direct Venture/Growth Fund LPpartnership	68K	0.1%	2026-01-23
2026-02-05	13D/Ano. 1	Adams Street 2017 Direct Venture/Growth Fund LPpartnership	88K	0.1%	2026-01-23
2026-02-05	13D/Ano. 1	Adams Street 2015 Direct Venture/Growth Fund LPpartnership	70K	0.1%	2026-01-23
2026-01-27	13D/Ano. 12	ORBIMED ADVISORS LLCinvestment adviser	8.6M	10.3%	2026-01-23
2026-01-27	13D/Ano. 12	ORBIMED CAPITAL GP V LLCother entity	8.6M	10.3%	2026-01-23

13F holders

Tracked managers holding CRVS at their latest 13F. JSON

4 of the 30 tracked managers held CRVS at their latest 13F, $35.3M in total at quarter-end prices. Millennium Management is the largest at $15.7M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 1 cut.

Fund	Quarter	Shares	Value	Of portfolio	Change in shares
Millennium Management	2026-06-30	1.0M	$15.7M	0.01%	+182K
Two Sigma Investments	2026-06-30	785K	$11.7M	0.01%	+245K
Citadel Advisors	2026-06-30	398K	$5.9M	0.00%	-45K
D. E. Shaw & Co.	2026-06-30	133K	$2.0M	0.00%	new

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

What this page is

Corvus Pharmaceuticals in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows Corvus Pharmaceuticals (CRVS), SEC CIK 1626971, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest: FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
Daily short volume: FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
Fails to deliver: SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-29.JSON and CSV
Large holders: SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-07.JSON and CSV
13F holders: SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Earnings dates: SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
Insider trades: SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-06-11.JSON and CSV
Company record: EDGAR filing index for CIK 1626971Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits: 10 requests a minute without a key, 30 with a free key from a free account.

How to read it

Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as pharmaceutical preparations

Other company pages

Datasets

Frequently Asked Questions

How much of CRVS is sold short?

17,967,756 shares were held short at the 2026-10-15 settlement, 14.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.

What is CRVS's daily short volume?

On 2026-11-02, 142,940 of the 219,403 CRVS shares reported to FINRA were sold short, 65.1% of the day's reported volume. Short volume is a flow for one day, not a position.

Does CRVS have fails to deliver?

The SEC's latest file shows 1,640 CRVS shares failed to deliver at settlement 2026-09-29. Fails are reported per settlement date and published twice a month with a lag.

Are CRVS insiders buying or selling?

No open-market insider trades were reported for CRVS in the last 90 days. The most recent filings are listed below. Latest filing: Moore David Scott (Director) on 2026-06-11.

Who owns 5% or more of CRVS?

Which tracked 13F managers own CRVS?

4 of the 30 tracked 13F managers held CRVS shares at their latest filing, $35.3M in all. The largest: Izzy Englander's Millennium Management (1.0M shares, $15.7M), Two Sigma Investments (785K shares, $11.7M), Ken Griffin's Citadel Advisors (398K shares, $5.9M), D. E. Shaw & Co. (133K shares, $2.0M).

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.